Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Kedudukan dalam Saham #36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Harga Saham
$1.73
Disegerakkan terakhir: 2025-06-17
Modal Pasaran
$2.55M
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
-79.71%
Negara
US
Perdagangan Eiger BioPharmaceuticals, Inc. (EIGR)

Kategori

Healthcare
Hasil untuk Eiger BioPharmaceuticals, Inc. (EIGR)
Hasil pada Dec 2023 TTM: $15.77M
Menurut laporan kewangan terkini daripada Eiger BioPharmaceuticals, Inc., hasil semasa syarikat (TTM) ialah $15.77M. Pada tahun 2022, syarikat memperoleh hasil sebanyak $13.48M peningkatan berbanding hasil pada tahun 2021 iaitu $12.14M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Eiger BioPharmaceuticals, Inc. dari 2016 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $15.77M 0.00%
2023 $15.77M 16.98%
2022 $13.48M 11.05%
2021 $12.14M 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 79,937.41%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 14,025.40%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 99,718.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 38,074.65%
NL